Dr. Reddy's Laboratories (RDY) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Dr. Reddy's Laboratories (RDY) has outperformed Summit Therapeutics (SMMT) over the past year, losing 11.9% versus a loss of 22.3%. Over five years, SMMT leads with a +241.6% price change compared with -5.5% for RDY. Summit Therapeutics is the larger company by market cap ($14.03 billion vs $10.40 billion), about 1.3 times the size.
Dr. Reddy's Laboratories pays a dividend yielding 64.10%, while Summit Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RDY | SMMT |
|---|---|---|
| Share price | $12.48 | $17.59 |
| Market cap | $10.40B | $14.03B |
| 1-day change | +2.30% | +2.45% |
| YTD return | -11.11% | +0.57% |
| 1-year return | -11.93% | -22.34% |
| 5-year return | -5.47% | +241.55% |
| P/E ratio (TTM) | 27.73 | — |
| Forward P/E | 19.45 | — |
| EPS (TTM) | $0.45 | $-1.14 |
| Dividend yield | 64.10% | 0.00% |
| Annual dividend | $8.00 | $0.00 |
| Revenue (latest FY) | $3.81B | — |
| Revenue growth (YoY) | +13.76% | — |
| Net income (latest FY) | $663.00M | $-1.08B |
| Gross margin | 58.51% | — |
| Operating margin | 22.09% | — |
| Net margin | 17.40% | — |
| 52-week high | $15.67 | $29.23 |
| 52-week low | $11.36 | $12.07 |
| Distance from 52-week high | -20.36% | -39.82% |
| Analyst consensus | none | buy |
| Avg. price target upside | +5.93% | +69.30% |
| Average volume | 2.87M | 5.87M |
| Shares outstanding | 832.99M | 797.75M |
| Employees | 27,527 | 265 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RDY has outperformed SMMT by 10.4 percentage points over the past year.
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (64.10% vs 0.00%).
- The two companies sit in different sectors: Dr. Reddy's Laboratories in Health Care and Summit Therapeutics in Healthcare.
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Healthcare · Biotechnology · 265 employees
RDY vs SMMT FAQ
Which is bigger, Dr. Reddy's Laboratories or Summit Therapeutics?
Summit Therapeutics (SMMT) is larger, with a market capitalization of $14.03B compared with $10.40B for Dr. Reddy's Laboratories (RDY).
Which stock has performed better over the past year, RDY or SMMT?
RDY returned -11.93% over the past 12 months, compared with -22.34% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Dr. Reddy's Laboratories or Summit Therapeutics?
Dr. Reddy's Laboratories pays a dividend yielding 64.10%, while Summit Therapeutics does not currently pay a regular dividend.
Are Dr. Reddy's Laboratories and Summit Therapeutics in the same industry?
No. Dr. Reddy's Laboratories is in the Health Care sector, while Summit Therapeutics is in Healthcare.